Gendered and heterosexual presumptive care settings are commonplace in health care and alienate sexual and gender minority (SGM) patients from receiving routine cancer screenings. Gendered references to gynecologic and breast cancers as “women’s cancer,” and prostate cancer as “men’s cancer,” are deeply rooted into the health care system. By disentangling gender from cancer and breaking down heteronormative assumptions, clinicians can provide equitable care to all patients, and critically, improve outcomes for SGM patients. National surveys and published literature show that SGM patients often delay cancer screenings and care for fear of stigma or mistreatment, which may result in later cancer diagnoses and poorer outcomes. Health care professionals who are trained in culturally relevant and humble care engage patients in discussions about the need for cancer screenings. Providing equitable care to SGM patients requires changing the practice environment, patient communications, and information-gathering processes to create an inclusive, affirming, and welcoming experience for diverse genders and sexual orientations. These changes can only be effective if the entire team, clinical and non-clinical staff alike, are trained in culturally relevant and humble education as they interact and care for SGM patients.
In this CMEO BriefCase, faculty will use case-based learning to demonstrate the challenges specifically related to gender assumptions that transgender and non-binary patients encounter when trying to access health care. Faculty will then provide learners with best practices on approaching conversations about cancer screening based on anatomy present, not by gender.
At the end of this CME/CE activity, participants should be able to apply efficacious and non-gendered approaches to symptom assessment.
Supported by an educational grant from Merck Sharpe & Dohme Corp.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in oncology, obstetrics, gynecology, infectious disease and/or primary care.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Dizon reports the following financial relationships: Consultant: DSMB/IDMC activities for AstraZeneca and Clovis Oncology. Research Institutional Support: Bristol Myers Squibb and Pfizer Inc. Other financial or material support: Board member for the LGBTQ Cancer Network.
Dr. Alpert reports no financial relationships.
Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-22-091-H01-P.